Table 2 Procedure characteristics of patients who underwent percutaneous coronary intervention with drug-eluting balloons
Full cohort | In-stent restenosis | De-novo lesions | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Variable | All patients | Non-CKD | CKD | P value | All patients | Non-CKD | CKD | P value | All patients | Non-CKD | CKD | P value |
Patient (n) | 362 | 261 | 101 | 101 | 65 | 36 | 261 | 196 | 65 | |||
Indication | < 0.05 | |||||||||||
Restenosis (%) | 101 (27.9%) | 65 (24.9%) | 36 (35.6%) | |||||||||
De novo (%) | 261 (72.1%) | 196 (75.1%) | 65 (64.4%) | |||||||||
ACS (%) | 238 (65.8%) | 174 (66.7%) | 64 (63.4%) | 0.6 | 59 (58.4%) | 34 (52.3%) | 25 (69.4%) | 0.1 | 179 (68.6%) | 140 (71.4%) | 39 (60.0%) | 0.1 |
Target vessel | 0.3 | 0.2 | 0.1 | |||||||||
LCX (%) | 134 (38.3%) | 95 (37.3%) | 39 (41.0%) | 29 (29.9%) | 22 (34.9%) | 7 (20.6%) | 105 (41.5%) | 73 (38.0%) | 32 (52.5%) | |||
LAD (%) | 147 (42.0%) | 113 (44.3%) | 34 (35.8%) | 41 (42.3%) | 24 (38.1%) | 17 (50.0%) | 106 (41.9%) | 89 (46.4%) | 17 (27.9%) | |||
LMCA (%) | 5 (1.4%) | 2 (0.8%) | 3 (3.2%) | 4 (4.1%) | 1 (1.6%) | 3 (8.8%) | 1 (0.4%) | 1 (0.5%) | 0 (0%) | |||
RCA (%) | 59 (16.9%) | 42 (16.5%) | 17 (17.9%) | 18 (18.6%) | 13 (20.6%) | 5 (14.7%) | 41 (16.2%) | 29 (15.1%) | 12 (19.7%) | |||
Graft (%) | 5 (1.4%) | 3 (1.2%) | 2 (2.1%) | 5 (5.2%) | 3 (4.8%) | 2 (5.9%) | 0 (0%) | 0 (0%) | 0 (0%) | |||
DEB- type | 0.1 | 0.6 | 0.01 | |||||||||
Pantera Lux (%) | 160 (45.6%) | 120 (47.2%) | 40 (41.2%) | 40 (41.2%) | 28 (44.4%) | 12 (35.3%) | 120 (47.2%) | 92 (48.2%) | 28 (44.4%) | |||
SeQuent Please (%) | 157 (44.7%) | 115 (45.3%) | 42 (43.3%) | 50 (51.6%) | 30 (47.6%) | 20 (58.8%) | 107 (42.1%) | 85 (44.5%) | 22 (34.9%) | |||
Both (%) | 34 (9.7%) | 19 (7.5%) | 15 (15.5%) | 7 (7.2%) | 5 (7.9%) | 2 (5.9%) | 27 (10.6%) | 14 (7.3%) | 13 (20.6%) | |||
Number of balloons | 1.1 ± 0.3 | 1.1 ± 0.2 | 1.1 ± 0.4 | 0.1 | 1.1 ± 0.3 | 1.1 ± 0.3 | 1.1 ± 0.3 | 0.9 | 1.1 ± 0.3 | 1.0 ± 0.2 | 1.1 ± 0.4 | 0.1 |
Size | 2.6 ± 0.6 | 2.6 ± 0.6 | 2.7 ± 0.6 | 0.5 | 3.0 ± 0.6 | 3.0 ± 0.6 | 3.0 ± 0.6 | 0.7 | 2.5 ± 0.5 | 2.5 ± 0.5 | 2.5 ± 0.5 | 0.9 |
Lesion length (mm) | 22.6 ± 6.5 | 22.7 ± 6.5 | 22.5 ± 6.4 | 0.8 | 22.3 ± 6.1 | 22.3 ± 6.1 | 22.5 ± 6.3 | 0.9 | 22.7 ± 6.6 | 22.8 ± 6.7 | 22.4 ± 6.5 | 0.7 |
DAPT- type | < 0.01 | 1 | < 0.005 | |||||||||
Prasugrel or Ticagralor (%) | 87 (24.0%) | 73 (28.0%) | 14 (13.9%) | 14 (13.9%) | 9 (13.9%) | 5 (13.9%) | 73 (28.0%) | 64 (32.7%) | 9 (13.9%) | |||
Clopidogral (%) | 275 (76.0%) | 188 (72.0%) | 87 (86.1%) | 87 (86.1%) | 56 (86.2%) | 31 (86.1%) | 188 (72.0%) | 132 (67.4%) | 56 (86.2%) | |||
DAPT duration- continues, months | ||||||||||||
All | 10.6 ± 3.7 | 10.9 ± 3.7 | 10.0 ± 3.4 | < 0.05 | 10.2 ± 3.3 | 10.4 ± 3.2 | 10.1 ± 3.4 | 0.8 | 10.8 ± 3.8 | 11.1 ± 3.8 | 9.8 ± 3.5 | < 0.005 |
Ambulatory cohort | 10.8 ± 3.6 | 11.3 ± 4.6 | 9.6 ± 3.3 | < 0.05 | 10.0 ± 3.3 | 9.8 ± 3.3 | 10.4 ± 3.6 | 0.7 | 11.2 ± 4.8 | 12.1 ± 5.0 | 9.2 ± 3.8 | 0.01 |
DAPT duration- categoric, < 6 month (%) | 54 (15.0%) | 33 (12.7%) | 21 (20.8%) | 0.1 | 18 (17.8%) | 12 (18.5%) | 6 (16.7%) | 1 | 36 (13.9%) | 21 (10.8%) | 15 (23.1%) | < 0.05 |